“The asset purchase of F351 and the subsequent business combination with Continent allows CBIO to both accelerate the return of cash to stockholders and provide additional value to our stockholders through equity ownership of Continent and a CVR for the monetization of our legacy assets. The company is continuing its efforts to monetize the legacy assets, and we expect to distribute additional cash in 2023. We believe that this set of transactions creates an attractive fibrosis company with further upside for our stockholders. Continent is profitable with a robust fibrosis pipeline in various stages of development, including a Phase 3 study of F351 in HBV associated fibrosis and a Phase 2 study poised to initiate in NASH fibrosis.”

—Nassim Usman, Ph.D., President and Chief Executive Officer, Catalyst Biosciences

Latest news

Dec 27, 2022

Catalyst Biosciences Completes First Steps in Reverse Merger Plan

Sep 01, 2022

Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share

Aug 25, 2022

Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share

X